Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Highland Long/Short Healthcare Fund Class Z (HHCZX)

12.13
Net Asset Value
+1.25%
1 Day
-10.94%
Year-to-Date
Overall Morningstar Rating
Long/short equity
Style or Category
No Load
Sales Expenses
2.42%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital appreciation. The fund seeks to achieve its investment objective by investing at least 80% of the value of its total assets (net assets plus any borrowings for investment purposes) under normal circumstances in securities of companies principally engaged in the design, development, production, sale, management or distribution of products, services or facilities used for or in connection with healthcare or medicine ("healthcare companies"). It is non-diversified.

Performance

1 month-5.97% 3 years+9.14%
3 months-12.52% 5 years+3.70%
1 year-19.84% Since inception+6.01%
Data through --

Peer Comparisonvs. Long/short equity

 HHCZXCategory
Performance 5-yr return+3.70%+4.45%
Expense ratio2.42%1.84%
Risk 5 year sharpe ratio0.330.44
Net assets$499.3M$297.1M
Average market cap$2.2B$45.8B
Average P/E--18.3
Portfolio turnover409%409%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyHighland Funds
Fund manager & tenureMichael Gregory / 5 Years
Minimal initial investment$2,500.00
Minimum IRA investment$50.00

Holdings

Cash61.04%
U.S. stock41.31%
Fixed income1.87%
International stock0.00%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 94.68%
Hardware 2.03%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Top 10 Holdings
Portfolio weighting
TMH TeamHealth Holdings Inc4.02%
THC Tenet Healthcare Corp3.33%
LDRH LDR Holding Corp3.18%
EW Edwards Lifesciences Corp2.23%
EGRX Eagle Pharmaceuticals Inc1.91%
ACHC Acadia Healthcare Company Inc1.79%
ICLR ICON PLC1.75%
ITCI Intra-Cellular Therapies Inc1.73%
IBB iShares Nasdaq Biotechnology ETF1.71%
AZN AstraZeneca1.67%

Partner Offers